Management of Acne Vulgaris
Publication Date: May 1, 2016
Recommendations
Grading and classification of acne
Clinicians may find it helpful to use a consistent grading/classification scale (encompassing the numbers and types of acne lesions as well as disease severity, anatomic sites, and scarring) to facilitate therapeutic decisions and assess response to treatment. (B)
Currently, no universal acne grading/classifying system can be recommended.
323935
Microbiologic testing
Routine microbiologic testing is not recommended in the evaluation and management of patients with acne. (B)
323935
Those who exhibit acne-like lesions suggestive of Gram-negative folliculitis may benefit from microbiologic testing. (B)
323935
Endocrinologic testing
Routine endocrinologic evaluation (eg, for androgen excess) is not recommended for the majority of patients with acne. (B)
323935
Laboratory evaluation is recommended for patients who have acne and additional signs of androgen excess. (B)
323935
Topical therapies
Benzoyl peroxide
Benzoyl peroxide or combinations with erythromycin or clindamycin are effective acne treatments and are recommended as monotherapy for mild acne, or in conjunction with a topical retinoid, or systemic antibiotic therapy for moderate to severe acne. (A)
323935
Benzoyl peroxide is effective in the prevention of bacterial resistance and is recommended for patients on topical or systemic antibiotic therapy. (A)
323935
Topical antibiotics
Topical antibiotics (eg, erythromycin and clindamycin) are effective acne treatments, but are not recommended as monotherapy because of the risk of bacterial resistance. (A)
323935
Topical retinoids
Topical retinoids are important in addressing the development and maintenance of acne and are recommended as monotherapy in primarily comedonal acne, or in combination with topical or oral antimicrobials in patients with mixed or primarily inflammatory acne lesions. (A)
323935
Combination therapy
Using multiple topical agents that affect different aspects of acne pathogenesis can be useful. Combination therapy should be used in the majority of patients with acne. (A)
323935
Topical adapalene, tretinoin, and benzoyl peroxide can be safely used in the management of preadolescent acne in children. (A)
323935
Azelaic acid is a useful adjunctive acne treatment and is recommended in the treatment of postinflammatory dyspigmentation. (A)
323935
Topical dapsone 5% gel is recommended for inflammatory acne, particularly in adult females with acne. (A)
323935
There is limited evidence to support recommendations for sulfur, nicotinamide, resorcinol, sodium sulfacetamide, aluminum chloride, and zinc in the treatment of acne. (D)
323935
Systemic antibiotics
Systemic antibiotics are recommended in the management of moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. ()
323935
Doxycycline and minocycline are more effective than tetracycline, but neither is superior to each other. (A)
323935
Although oral erythromycin and azithromycin can be effective in treating acne, its use should be limited to those who cannot use the tetracyclines (ie, pregnant women or children <8 years of age). Erythromycin use should be restricted because of its increased risk of bacterial resistance. (A)
323935
Trimethoprim-sulfamethoxazole and trimethoprim use should be restricted to patients who are unable to tolerate tetracyclines or in treatment-resistant patients. (B)
323935
Use of systemic antibiotics, other than the tetracyclines and macrolides, is discouraged because there are limited data for their use in acne. Trimethoprim-sulfamethoxazole and trimethoprim use should be restricted to patients who are unable to tolerate tetracyclines or in treatment-resistant patients (A)
323935
Systemic antibiotic use should be limited to the shortest possible duration. Re-evaluate at 3-4 months to minimize the development of bacterial resistance. Monotherapy with systemic antibiotics is not recommended. (A)
323935
Concomitant topical therapy with benzoyl peroxide or a retinoid should be used with systemic antibiotics and for maintenance after completion of systemic antibiotic therapy. (A)
323935
Hormonal agents
Estrogen-containing combined oral contraceptives are effective and recommended in the treatment of inflammatory acne in females. (A)
323935
Spironolactone is useful in the treatment of acne in select females. (B)
323935
Oral corticosteroid therapy can be of temporary benefit in patients who have severe inflammatory acne while starting standard acne treatment. (B)
323935
In patients who have well documented adrenal hyperandrogenism, low-dose oral corticosteroids are recommended in treatment of acne. (B)
323935
Use of flutamide in the treatment of acne is discouraged except where benefit warrants the risk. (C)
323935
Isotretinoin
Oral isotretinoin is recommended for the treatment of severe nodular acne. (A)
323935
Oral isotretinoin is appropriate for the treatment of moderate acne that is treatment-resistant or for the management of acne that is producing physical scarring or psychosocial distress. (A)
323935
Low-dose isotretinoin can be used to effectively treat acne and reduce the frequency and severity of medication-related side effects. Intermittent dosing of isotretinoin is not recommended. (A)
323935
Routine monitoring of liver function tests, serum cholesterol, and triglycerides at baseline and again until response to treatment is established is recommended. Routine monitoring of complete blood count is not recommended. (B)
323935
All patients treated with isotretinoin must adhere to the iPLEDGE risk management program. (A)
323935
Females of child-bearing potential taking isotretinoin should be counseled regarding various contraceptive methods including user-independent forms. (A)
323935
Prescribing physicians also should monitor their patients for any indication of inflammatory bowel disease and depressive symptoms and educate their patients about the potential risks with isotretinoin. (A)
323935
Miscellaneous therapies and physical modalities
There is limited evidence to recommend the use and benefit of physical modalities for the routine treatment of acne, including pulsed dye laser, glycolic acid peels, and salicylic acid peels. (B)
323935
Intralesional corticosteroid injections are effective in the treatment of individual acne nodules. (C)
323935
Complementary and alternative therapies
Herbal and alternative therapies have been used to treat acne. Although most of these products appear to be well tolerated, limited data exist regarding the safety and efficacy of these agents to recommend their use in acne. (B)
323935
Role of diet in acne
Given the current data, no specific dietary changes are recommended in the management of acne. (B)
323935
Emerging data suggest that high glycemic index diets may be associated with acne. (B)
323935
Limited evidence suggests that some dairy, particularly skim milk, may influence acne. (B)
323935
Title
Management of Acne Vulgaris
Authoring Organization
American Academy of Dermatology
Publication Month/Year
May 1, 2016
External Publication Status
Published
Country of Publication
US
Document Objectives
This guideline addresses the management of adolescent and adult patients who present with acne vulgaris (AV). This document will discuss various acne treatments, including topical therapies, systemic agents, and physical modalities, including lasers and photodynamic therapy. In addition, grading/classification system, microbiology and endocrinology testing, complementary/alternative therapies, and the role of diet will be reviewed.
Target Patient Population
Patients with acne vulgaris
Inclusion Criteria
Female, Male, Adolescent, Adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening, Management, Treatment
Diseases/Conditions (MeSH)
D013256 - Steroids, D013754 - Tetracyclines, D000152 - Acne Vulgaris, D000287 - Administration, Topical
Keywords
acne vulgaris, acne management, topical antibiotics, antibiotics
Methodology
Number of Source Documents
315
Literature Search Start Date
May 1, 2006
Literature Search End Date
September 1, 2014